fampridine

AMPYRA, which was previously referred to as Fampridine-SR, is an extended release tablet formulation of dalfampridine 4-aminopyridine, 4-AP, which was previously called fampridine, and remains known by that name outside the US.

unknown title 2011

AMPYRA, which was previously referred to as Fampridine-SR, is an extended release tablet formulation of dalfampridine 4-aminopyridine, 4-AP, which was previously called fampridine, and remains known by that name outside the US.

unknown title 2011

He added that Ampyra, which was previously referred to as fampridine-SR, is the only medication indicated for this use.

PharmaTimes World News 2010

The U.S. Food and Drug Administration has approved the marketing of Ampyra ™ (dalfampridine, formerly known as fampridine S., from Acorda Therapeutics) for its ability to improve walking speed in people with any type of multiple sclerosis.

THE MEDICAL NEWS 2010

Ampyra, formerly known as fampridine SR, is a tablet containing a sustained-release formula of 4-aminopyridine, which blocks tiny pores, or potassium channels, on the surface of nerve fibers.

THE MEDICAL NEWS 2010

AMPYRA is an extended release tablet formulation of the investigational drug dalfampridine (4-aminopyridine and called fampridine outside the U.S.).

The Earth Times Online Newspaper 2010

Test Drug Improves Walking Ability in Some Multiple Sclerosis Patients: Research An experimental drug called fampridine improves walking ability in some patients with multiple sclerosis (MS), a disease of the nervous system that crimps mobility, a study published on Frid ...

Medindia Health News 2009

Less than a month after the Food and Drug Administration said there was a problem with its application, Acorda Therapeutics delivered a new drug application for fampridine-sr, its treatment for multiple sclerosis.

Selloff Stings Conmed and NCR but Spares Acorda 2009

AMPYRA should not be taken with other forms of 4-aminopyridine 4-AP, fampridine, since the active ingredient is the same.

unknown title 2011

On July 20, the European Commission granted conditional approval for FAMPYRA ® (prolonged-release fampridine tablets) to improve walking in adult patients with multiple sclerosis (MS) who have walking disabilities (EDSS 4-7).

unknown title 2011